ClinicalTrials.gg
CompletedNCT03206346Updated Jul 2, 2017

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

A Phase 3 interventional study of Ingavirin and Placebo oral capsule in Influenza, Human, Acute Respiratory Infection and Viral Infection, sponsored by Valenta Pharm JSC. Completed at 5 sites in Russian Federation. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 5 months after the study started (first participant enrolled Jan 2012, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.

Enrollment
10th of 15
161 · median 240
Started
2012
the only one that year
Phase 3
7 of 15
none open now
Registered
5th of 15
by date

Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 5th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Valenta Pharm JSC, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 13-17 years old patients.

03

Conditions studied

  • Influenza, Human
  • Acute Respiratory Infection
  • Viral Infection
  • Common Cold
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The form signed by the patient's parent/adoptive parent to participate in the clinical study
  • Male and female patients aged 13-17
  • Patients with moderate course of influenza or other acute respiratory viral infections (AVRI)
  • Patients with clinically diagnosed influenza or other ARVI based on the body temperature > 37,5 ° C, not less than 1 of the following other symptoms of intoxication and not less than 1 of the following of catarrhal symptoms:
  • Intoxication symptoms: headache, malaise, myalgia, pain in the eyeballs;
  • Catarrhal symptoms: sore throat, rhinorrhea, cough, nasal congestion
  • Uncomplicated course of influenza and other ARVI
  • Interval between onset of symptoms and enrollment to the study of not more than 36 hours

Exclusion criteria

Exclusion Criteria:

  • Complicated course of influenza and other acute respiratory viral infections
  • Treatment with antiviral drugs (antivirals, interferons and interferon inducers), drugs with immunomodulatory effects or antibiotics with systemic and local action within 7 days prior to the screening visit
  • Severe influenza or other ARVI with symptoms of cardiovascular disease, and other symptoms of infectious-toxic shock, and meningoencephalitic syndromes
  • Signs of primary viral pneumonia development (presence of two or more of the following symptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullness of percussion sound at symmetrical assessment of the upper and lower parts of the lungs
  • Infectious diseases within the last week prior to enrollment
  • "RRI children" (incidence of ARVI within the last 12 months is 6 times or more)
  • Asthma history
  • History of increased seizure activity
  • Severe decompensated or unstable medical or psychiatric conditions (any diseases or conditions that threaten the life of the patient or worsen the patient's prognosis and also make it impossible to conduct a clinical study in the patient).
  • Cancer, infection, tuberculosis, including those in history
  • to imidazolyl ethanamide pentandioic acid and/or of Ingavirin product
  • Diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption, deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucose malabsorption, deficiency of glucose-6-phosphate dehydrogenase
  • Participation of the patient in any other clinical trial within the last 90 days prior to enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Ingavirin

    Broad spectrum antiviral drug

    Drug: Ingavirin

  • Placebo comparator
    Placebo oral capsule

    Placebo capsule identical in appearance to Ingavirin capsule

    Drug: Placebo oral capsule

Interventions

  • Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.

    Also known as: Imidazolyl ethanamide pentandioic acid

  • DrugPlacebo oral capsule

    Placebo, capsules daily for 5 days.

06

What researchers measure

Primary outcomes

  1. Time to resolution of fever

    Time from the start of study treatment to resolution of fever ( t ≤ 36,9 ºС)

    Time frame: 7 ± 1 days

Secondary outcomes

  1. Time to resolution of intoxication symptoms

    Time from the start of study treatment to resolution of all intoxication symptoms.

    Time frame: 7 ± 1 days

  2. Time to resolution of catarrhal symptoms

    Time from the start of study treatment to resolution of all catarrhal symptoms.

    Time frame: 7 ± 1 days

  3. Time to resolution/alleviation of cough

    Time from the start of study treatment to resolution/alleviation of cough

    Time frame: 7 ± 1 days

Other outcomes

  1. Proportion of subjects with development of complications of Influenza or other acute respiratory viral infection

    Proportion of subjects who developed complications during treatment period (7 ± 1 days) and follow-up period (21 ± 1 days)

    Time frame: 7 ± 1 days and 21 ± 1 days

07

Study locations

5 sites
  • GBOU VPO "Kazan State Medical University" of Ministry of Health of Russian Federation
    Kazan', 420012, Russian Federation
  • City Pediatric Outpatient Clinic number 5
    Perm, 614066, Russian Federation
  • Research Institute of Influenza, Ministry of Healthcare of Russian Federation
    Saint Petersburg, 197376, Russian Federation
  • Saratov State Medical University named after V. I. Razumovsky
    Saratov, 410012, Russian Federation
  • GBOU VPO "Yaroslavl State Medical University" of Ministry of Health of Russian Federation
    Yaroslavl, 150000, Russian Federation
08

References and documents

Publications

  • A.A.Shul'dyakov, E.P.Lyapina, V.I.Kuznetsov, N.I.Zryachkin, I.G.Sitnikov, O.A.Perminova, V.A.Anokhin4, G.R.Fatkullina. New possibilities in therapy of acute respiratory viral infections in children. Vopr. Prakt. Pediatrii. 2015 vol10 n5 pp21-28. Russian

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Nov 2012, 10 months.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 10 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jul 2, 2017
StartActual
Jan 2012
Primary completionActual
Nov 2012
CompletionActual
Aug 2013
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03206346
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Jan 2012
Primary completion
Nov 2012
Completion
Aug 2013
Last update
Jul 2, 2017

Study contacts

Ekaterina Zakharova, MD, PhD
study director · Valenta Pharm JSC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion